Please ensure Javascript is enabled for purposes of website accessibility

Masimo Corporation Full-Year 2017 Outlook Improves After a Strong Q1 Performance

By Keith Speights – Updated May 8, 2017 at 10:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The non-invasive monitoring technologies leader reports higher revenue and earnings on solid shipments of its pulse oximetry products.

When Masimo Corporation (MASI 0.17%) announced its fourth-quarter 2016 results in February, investors beamed. The maker of non-invasive monitoring technologies handily beat expectations.

Masimo announced its first-quarter 2017 results on May 3. Shareholders again had reason to remain enthusiastic about the stock and its future prospects. Here's why.

Pulse oximeter

Image source: Getty Images.

Masimo results: The raw numbers


Q1 2017 

Q1 2016 

Change (YOY)


 $186.3 million $171.2 million 


Net income from continuing operations

 $45.3 million $27.6 million 


Earnings per diluted share

 $0.82 $0.53 


Data source: Masimo Corporation. 

What happened with Masimo this quarter?

Direct product sales continued to be the primary source of revenue for Masimo in the first quarter, accounting for 87% of total product revenue. And these sales continued to grow -- they were up 9.9% year over year. Original equipment manufacturer (OEM) sales in the first quarter generated 13% of revenue and increased 3.7% year over year. The only real negative for Masimo's top line was related to sales of its rainbow products, which declined 17.7% in the first quarter.  

Net income in the first quarter received a big boost from a $1.3 million tax benefit, whereas a relatively large tax hit of $10.3 million was incurred in the prior-year period. Masimo's improved revenue situation also trickled down to the company's bottom line.

Masimo's spending increased somewhat during the first quarter, but there doesn't appear to be any reason for concern. Total operating expenses increased by 5.3% year over year. Higher selling, general, and administrative costs (SG&A) were the primary factor behind this increase, although Masimo's research and development spending also rose from the prior-year period.

The company shipped around 47,900 SET pulse oximeters and rainbow SET pulse oximeters during the first quarter, not counting handheld and finger oximeters. With those shipments, Masimo now has a worldwide installed base of oximetry products of more than 1.5 million units as of April 1, 2017 -- a 6.1% increase from a year ago.

Masimo ended the first quarter with cash and cash investments totaling $343.8 million. That's a nice jump from the $306 million reported at the end of 2016. During the first quarter, Masimo generated $15.4 million in operating cash flow. The company also received $27.3 million in proceeds from stock option exercises.

What management had to say

Masimo chairman and CEO Joe Kiani said, "Our first-quarter results illustrate the strength in our business as we continue to see broad adoption of our products on a global basis, evidenced by our third highest quarterly product shipments on record."

Looking forward

Thanks to its solid performance in the first quarter, Masimo now has greater expectations for the rest of 2017. The company raised its full-year 2017 financial guidance.

Masimo now expects 2017 revenue of approximately $759 million, up from the $752 million given in its previous guidance. The company projects full-year product revenue of $727 million, up from $721 million. Royalty revenue is expected to come in at $32 million, compared to $31 million in Masimo's previous guidance. The company projects full-year 2017 earnings per diluted share of approximately $2.65. That's a hefty jump from the $2.30 per diluted share given in its previous guidance.

After the nice start in the first quarter, investors have reason to expect good things ahead. As has been the case for a while, the biggest risk for Masimo is its relatively high valuation. Any bump in the road could cause the stock to fall. For now, though, Masimo's business appears to be in great shape.

Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Masimo. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.